Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | 8274J | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | XL223 | — |
Administration after temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a male patient who received Men ACWY-CRM NVS (Menveo) (batch number XL223) for prophylaxis. Co-suspect products included Men B NVS (Bexsero) (batch number 8274J) for prophylaxis. On 23-APR-2025, the patient received Menveo and Bexsero. On an unknown date, an unknown time after receiving Menveo and Bexsero, the patient experienced incorrect storage of drug (Verbatim: Administration after temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 29-APR-2025 Reporter stated that between the time that the excursion happened there was 8 vaccines vaccines administered and asked if that's completely fine. The patient received Bexsero and Menveo (1 vial). Patient received vaccines after temperature excursion, which led to incorrect storage of drug. This case is one of the three linked cases, reported by the same reporter.; Sender's Comments: US-GSK-US2025051843:same reporter/different patient US-GSK-US2025051844:same reporter/different patient